Shree Ganesh Remedies Ltd
NSE: SGRL · Pharmaceuticals · sector
₹633.05NSE close 2026-10-26
Key numbers
Market cap₹813 cr
Price₹633.05
52w high / low₹750 / ₹477
P/E52.7xSector median 27.9x
P/B5.0xSector median 2.9x
Book value₹127.0
Dividend yield–Sector median 0.48%
ROE10.0%Sector median 11.7%
ROCE12.3%Sector median 12.3%
OPM31.4%Sector median 14.0%
Debt / equity0.19xSector median 0.16x
EV/EBITDA26.3xSector median 18.6x
Interest cover8.1x
Current ratio3.96x
Sales growth 3y+6.6%Sector median +9.6%
Profit growth 3y+1.4%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹26 cr vs borrowings ₹31 cr (FY26): borrowings are higher by ₹5 cr.
- Operating profit covered interest 8.1x in the last 12 months.
- Other income was 21% of net profit in the last 12 months.
- Dividend paid in 3 of the last 5 financial years.
- Price ₹633.05 on 2026-10-26: -15.6% from the 52-week high, +32.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹853.95 · low ₹417.95
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 24 | 25 | 30 | 21 | 33 | 14 |
| EBITDA | 10 | 7 | 10 | 7 | 11 | 3 |
| OPM % | 40.4% | 29.6% | 31.7% | 31.9% | 34.2% | 23.3% |
| Other income | 2 | 1 | 1 | 1 | 1 | 1 |
| Net profit | 7 | 3 | 5 | 3 | 6 | 1 |
| EPS (₹) | 5.13 | 2.68 | 3.86 | 2.41 | 4.88 | 0.87 |
| Revenue YoY | +35.9% | -41.8% | ||||
| Profit YoY | -4.9% | -67.5% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 71 | 90 | 126 | 109 | 109 | 99 |
| EBITDA | 18 | 23 | 42 | 39 | 35 | 31 |
| Net profit | 13 | 17 | 28 | 23 | 18 | 15 |
| EPS (₹) | 11.16 | 13.86 | 22.35 | 17.96 | 13.83 | 12.02 |
| Revenue growth | +26.6% | +39.5% | -13.7% | +0.6% | – | |
| Profit growth | +27.0% | +65.2% | -18.0% | -23.0% | – | |
| Dividend / share (₹) | 1.75 | 0.50 | 0.50 | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +6.6% | – | – |
| Net profit | +1.4% | – | – |
| EPS | -0.1% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 145 | 163 |
| Borrowings | 38 | 31 |
| Cash & equivalents | 28 | 26 |
| Total assets | 192 | 208 |
| Fixed assets | 58 | 68 |
| Capital work in progress | 8 | 12 |
| Investments | 0 | 0 |
| Receivables | 22 | 33 |
| Inventory | 22 | 24 |
| Payables | 6 | 9 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 31 | 24 |
| Cash from investing | -36 | -10 |
| Cash from financing | -1 | -12 |
| Capex | 23 | 17 |
| Free cash flow | 7 | 7 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 15.9% | 10.9% |
| ROCE % | 18.2% | 14.2% |
| Debtor days | 75 | 109 |
| Inventory days | 224 | 209 |
| Payable days | 61 | 82 |
| Cash conversion cycle (days) | 238 | 236 |
| Working capital days | 206 | 214 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SGRL | ₹813 cr | 52.7x | 5.0x | 10.0% | 12.3% | 31.4% | +6.6% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2023-09-07 | Dividend | Final Dividend Rs 0.5 |
| 2022-09-15 | Dividend | Final Dividend Rs 0.5 |
| 2021-09-08 | Dividend | Final Dividend Rs 1.75 |
| 2020-09-01 | Dividend | Final Dividend Rs 1.5 |
| 2019-08-22 | Dividend | Final Dividend Rs 1.25 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SGRL |
| BSE code | 540737 |
| ISIN | INE414Y01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.